Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Using Synapse for Your Cefdinir Research: An Easy Guide
Drug Insights
2 min read
Using Synapse for Your Cefdinir Research: An Easy Guide
11 February 2024
Cefdinir, marketed under the brand name Omnicef, is a small molecule drug that acts as a penicillin-binding protein (PBP) inhibitor and a cell wall inhibitor.
Read →
FDA Approves NeuroBo Pharmaceuticals' Phase 1 Study of Obesity Drug DA-1726
Latest Hotspot
3 min read
FDA Approves NeuroBo Pharmaceuticals' Phase 1 Study of Obesity Drug DA-1726
11 February 2024
NeuroBo Pharmaceuticals has received approval from the FDA for a Phase 1 clinical study of DA-1726, a new drug aimed at managing obesity.
Read →
Accessing Fluconazole Information on Synapse: A Step-by-Step Approach
Drug Insights
2 min read
Accessing Fluconazole Information on Synapse: A Step-by-Step Approach
11 February 2024
Fluconazole is a small molecule drug used to treat various fungal infections. It is sold under the trade names Diflucan, Zoltec, and Loitin.
Read →
Halia Therapeutics Revels $30M Series C Funding for Inflammation Treatments
Latest Hotspot
3 min read
Halia Therapeutics Revels $30M Series C Funding for Inflammation Treatments
11 February 2024
Halia Therapeutics has unveiled a $30 million Series C funding round to further develop their innovative range of treatments for inflammation.
Read →
Maximize Your Synapse Use: Your Guide to Searching Meclizine
Drug Insights
2 min read
Maximize Your Synapse Use: Your Guide to Searching Meclizine
11 February 2024
Meclizine is a small molecule drug that acts as an antagonist of histamine (H1) receptors.
Read →
Bio-Thera Solutions Initiates Phase 1B/2A Study for BAT6026 Monoclonal Antibody in Eczema Treatment
Latest Hotspot
3 min read
Bio-Thera Solutions Initiates Phase 1B/2A Study for BAT6026 Monoclonal Antibody in Eczema Treatment
9 February 2024
Bio-Thera Solutions has launched an early-stage clinical study, specifically Phase 1B/2A, for its novel monoclonal antibody, BAT6026, aimed at OX40 for treating individuals experiencing moderate to intense eczema.
Read →
Master Rosuvastatin Search on Synapse
Drug Insights
2 min read
Master Rosuvastatin Search on Synapse
9 February 2024
Rosuvastatin, sold as Ezallor and Crestor, is a small molecule inhibiting liver cholesterol synthesis by blocking HMG-CoA reductase enzyme.
Read →
New Insights: Vabysmo Effectively Treats Retinal Swelling in Retinal Vein Occlusion Patients
Latest Hotspot
3 min read
New Insights: Vabysmo Effectively Treats Retinal Swelling in Retinal Vein Occlusion Patients
9 February 2024
Recent findings on Genentech's drug Vabysmo indicate persistent efficacy in reducing retinal swelling and enhancing eyesight for those with Retinal Vein Occlusion.
Read →
Unveiling Escitalopram: How to Search for it on Synapse
Drug Insights
2 min read
Unveiling Escitalopram: How to Search for it on Synapse
9 February 2024
Escitalopram, marketed under the trade name Esertia, is an orally administered selective serotonin reuptake inhibitor.
Read →
First Participant Dosed in RS Oncology's Phase 2 Trial of RSO-021 for Chest Tumor and Lung Metastases
Latest Hotspot
3 min read
First Participant Dosed in RS Oncology's Phase 2 Trial of RSO-021 for Chest Tumor and Lung Metastases
9 February 2024
RS Oncology Confirms Initial Participant Receives Dosage in Stage 2 Trial (MITOPE) Examining RSO-021 in Malignant Chest Tumor and Lung Metastases Therapy.
Read →
Expert Tips for Searching Ketamine on Synapse
Drug Insights
2 min read
Expert Tips for Searching Ketamine on Synapse
9 February 2024
Ketamine is a small molecule drug that acts as a modulator at the N-methyl-D-aspartate (NMDA) receptor.
Read →
Sirius Therapeutics Launches Phase One Study for Innovative Anticoagulant to Combat Thromboembolic Conditions
Latest Hotspot
3 min read
Sirius Therapeutics Launches Phase One Study for Innovative Anticoagulant to Combat Thromboembolic Conditions
9 February 2024
Sirius Therapeutics has initiated a first-stage clinical study for an advanced, extended-duration Factor XI siRNA anticoagulant, aimed at addressing thromboembolic conditions.
Read →